Usman Azam, MD is the Global Head of the Cell & Gene Therapies Unit at Novartis Pharmaceuticals. Dr. Azam has extensive pharmaceutical and biotechnology industry experience in science, regulatory and commercial roles across a variety of disease areas. During his tenure at Novartis, Dr. Azam held prominent roles in Medical Affairs, Health Economics Outcomes Research, and Regulatory Affairs. Prior to Novartis, he founded Novaccel Therapeutics LLC, focused on accelerating assets in translational medicine. He held previous leadership roles at Aspreva Pharmaceutics, Johnson & Johnson and GlaxoSmithKline. Dr. Azam is a board certified obstetrician and gynecologist and is published in peer reviewed journals.

Luciano Rossetti – Head of Global Research & Development Luciano Rossetti, MD, is Executive Vice President, Global Head of Research & Development and a member of the Pharmaceutical Executive Committee.Before joining Merck Serono, Rossetti acted as Senior Vice President Late Stage Development at Merck Sharp & Dohme, or MSD. In this position, he was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas. At MSD, he played a key role in shaping and implementing the development strategy of several potential breakthrough compounds such as Anti PD-1. He also restructured the clinical genetics group to better leverage the collaboration between discovery and clinical development.

Judy Stenmark is Director General of The Global Self-Care Federation. The Federation represents associations and manufacturers in the self-care industry, and works with its members and stakeholder groups to ensure evidence-based self-care products and solutions are recognized as key contributors to better health. Judy previously spent eight years as head of the International Osteoporosis Foundation (IOF) in Switzerland, and prior to that nine years heading up national not-for-profit organisation, Osteoporosis Australia.

Professor Germain Ntono Tsimi is Former Head of the Division of Academic Affairs, Education and Research; Vice Dean in charge of Academic Affairs and programming at the Faculty of Laws and Political Science; and Head of Department of Academic Affairs and Cooperation at the University of Yaoundé II. He will serve as the UYII-IFPMA Chair President on "Health and Globalization: Laws, Policies and Market."

Cyntia Genolet joined IFPMA in 2012 to work as the responsible for the anti-counterfeiting portfolio. In addition to this role, she leads since 2017 IFPMA engagement in Africa and deals with other Global Health policies. She also worked on policy issues related to biotherapeutic and regulatory domains. Cyntia holds a master’s degree in International Relations from the Graduate Institute of International and Development Studies in Geneva and a master’s of advanced studies in Health Economics and Management from HEC Lausanne.
Prior to joining IFPMA, she has worked for Sanofi in the office of relations with the International Institutions, in Geneva. She has built her professional experience working for NGOs, international organizations and governments in Africa, South America and Switzerland.

Kawaldip oversees the strategy and direction of IAPO. He joins with extensive public health experience at national and international level.

Kawaldip previously held the position of CEO at Richmond Psychosocial Foundation International and worked as Managing Director of Coram Children’s Legal Centre. He has European and international public health experience as Director of the Global Health Inequalities Programme and as Chairman of the European Network of Quitlines.

Kawaldip’s qualifications include an MSc in the Public Health International Programme from the London School of Hygiene and Tropical Medicine, an MBA in Business Administration from the London Business School and Open University, and an LLB (Hons) from the London College of Law.

Dr Cary Adams is the Chief Executive Officer of the Union for International Cancer Control (UICC). He has a background in Economics, Computing and Statistics and is a Harvard Business School Alumni having attended the School’s Executive General Management programme in 2003. In 2014 he was awarded an Honorary Doctorate in International Relations from the University for Business and International Studies in Geneva, and in 2015 an Honorary Doctorate in Health from Bath University in the UK. In May 2015, Cary was awarded ‘CEO of the year’ at the International and European Association conference organised by the Associations Network.

David Neal is Head of Policy at Polygeia and a final year medical student at the University of Cambridge. He holds a first class BA (Hons) degree in psychology and biological anthropology from the University of Cambridge and has worked at the World Health Organisation and Public Health Laboratory Ivo de Carneri, Zanzibar.

Ramanan Laxminarayan is founder and director of the Center for Disease Dynamics, Economics & Policy (CDDEP) in Washington, D.C., and a senior research scholar and lecturer at the Princeton Environmental Institute at Princeton University. He is an affiliate professor at the University of Washington and a visiting professor at the University of Kwazulu Natal. Laxminarayan is founder of HealthCube, which works to improve access to healthcare and diagnostics worldwide.

Rhys Wenlock is a third year Medical Student at Downing College, Cambridge and a researcher at Polygeia, a global health think-tank based at University of Cambridge. His global health research focuses on how the problems uncovered as a part of the international Ebola response could direct future development and health systems strengthening. Through the summer he will be working in Dar Es Salaam, Tanzania with the Cambridge Development initiative (CDI) to improve access to healthcare for marginalized communities.

Abigail Wood is a researcher with Polygeia, a global health think-tank based at University of Cambridge, where she is studying biochemistry. Her research interests focus on infectious diseases and she has project experience in strategic policy work for Lepra, a UK-based charity tackling leprosy, tuberculosis and other major infectious diseases. Abigail also serves as President of BlueSci, the Cambridge University Science Communications Society.

Director: DRA Head – South Africa and Southern Africa Country Group at Novartis
Dakshina held numerous regulatory positions in the pharmaceutical industry over the last 15 years based in South Africa. He has been with Novartis for 3.5 years managing the regulatory affairs function in this region. He has also provided support in regulatory policy and practice in the African region via his association with the IFPMA’s Africa Regulatory Network over the last 3 years. Within his position in Novartis, his achievements included a multitude of product submissions and registrations through the implementation of innovative strategies. In addition, he has also been invited into the pilot regulatory harmonisation project; ZAZIBONA project in the SADC region.

General Delegate of Fondation Chirac for Access to quality healthcare and medicines, Marc Gentilini is also President of the association OPALS (PanAfrican Organization for the Fight against AIDS) and Honorary President of the French Academy of Medicine. Grand Officer of the Légion of Honor, he has also been President of the French Red Cross from 1997 to 2004. Professor Marc Gentilini is a well-know specialist of the tropical diseases and has headed from 1970 to 1998 the department of neglected tropical diseases of the Hospital of La Pitié-Salepêtrière (Paris).

Paul Dearden is since May 2014 AbbVie’s Director, Regulatory Policy & Intelligence. Prior to that, he held various self employed consultancy assignments for 6 years. From 2004 to 2008, he worked at Brathay Learning & Development in a commercial role as Head of Corporate Business. He also stayed for 8 years with GSK’s and GlaxoWellcome R&D Ltd sepraretly and led their international regulatory affairs Policy & Intelligence group and before that various emerging markets responsibilities. He started his career as Senior Regulatory Executive of The Wellcome Foundation Ltd from 1993 to 1996.Paul Dearden holds a BSc Hons Degree in Physiology & Pharmacology from Manchester University, UK.

Ms Estelle Michael, Senior Regulatory Policy Director, AstraZeneca and member of the IFPMA Regulatory Policy and Technical Standards Committee (RPTS). Estelle is currently focused on driving policy and advocacy for key emerging markets and is an active member of the Regulatory Policy and Technical Standards Committee (RPTS) of IFPMA.

Dr Konji Sebati is the current CEO of IPASA, the Innovative Pharmaceutical Association of South Africa. Konji has over 25 years’ experience in the Public and Private sector. Konji served as a Medical Officer in Paediatrics and Child Health for several years before managing 21 Primary Health Care clinics in Pretoria. She joined the private sector working first with Roche as Medical Advisor and then with Pfizer Pharmaceuticals as a senior Executive in Medical and Corporate Affairs, in South Africa and at the Pfizer Headquarters New York. In 2004 she was appointed South Africa’s Ambassador to Switzerland, The Vatican and Liechtenstein, and in 2008 was appointed Ambassador to France, UNESCO and the OECD. She worked as an International Civil Servant working for a United Nations Agency, WIPO, the World Intellectual Property Organisation, based in Geneva, as senior Director heading the Department of Traditional Knowledge and Global Challenges. Konji’s latest achievement was being appointed to the Board of the Medicines for Malaria Venture (MMV).

Konji has a Bachelor of Science degree from the University of the North (now University of Limpopo), an MBChb degree from University of Nairobi/Kenyatta Hospital, Kenya, a Diploma in Child Health from the College of Medicine, South Africa, and a Diploma in Public Health Planning and Health Services Management from the University of Witwatersrand.

Dr Abraham Palache is founder of FluPal Consultancy BV, a private company that provides expertise and services to Abbott, among others, in the field of influenza and influenza vaccinology. He’s co-founder of the European Scientific Working Group on Influenza (ESWI), a founding member of IFPMA’s Influenza Vaccine Supply International Task Force (IVS) where since 2004 he chairs the Policy Practice and Communication subgroup (PPC) of this group. He is also a member of the External Affairs Working Group of the Association of the European Vaccine Manufacturers (EVM). In 2006, he joined the Asia-Pacific Advisory Committee on Influenza (APACI) group as an industry representative. He served for more than 40 years Abbott Biologicals as Clinical Research Project leader, Director of Public Affairs for influenza and Global Government Affairs Director for Vaccines.

Greg Perry joined IFPMA on 1st February 2018, and has responsibility for IFPMA’s external outreach and stakeholder engagement in global health topics including innovation, access, and the international regulatory environment. Greg Perry brought with him more than 20 years’ leadership and advocacy experience in the public healthcare arena.

Prior to joining IFPMA, Greg worked as Executive Director of the Medicines Patent Pool, which he joined in 2013 and as Director General of the European Generic Medicines Association (1999 - 2013) in Brussels. Previously he worked as a partner in a UK public affairs company as a European Union policy advisor to corporate and non-governmental organizations, and before that as a Parliamentary Advisor to Members of the European Parliament. Greg is a Member of the Advisory Council of the Organization for Professionals in Regulatory Affairs (TOPRA) and is a former member of the Standing Advisory Committee before the European Patent Office (SACEPO). Greg also holds the Golden Cross of Merit of the Republic of Poland.

David Stewart is a Consultant, Health and Nursing Policy, for the International Council of Nurses. Prior to this role, he worked for the Queensland Government as a Director of Nursing in the Office of the Chief Nursing and Midwifery Officer. He has over 22 years’ experience in the health and government sector. David has expertise in public policy development and management and has worked in governance and development roles.

Eric de Roodenbeke is the CEO of the International Hospital Federation, a not for profit, non-governmental membership organization. Its members are worldwide hospitals and healthcare organizations having a distinct relationship with the provision of healthcare.

Prior to joining the IHF, between July 2007 and May 2008, Mr. de Roodenbeke was Senior Health Specialist at the World Health Organization (WHO) for the Global Health Workforce Alliance (GHWA) during which time he was involved in support country action programs to develop a response to the HRH crisis; development of strategies for regional networks in support of HRH development and was the focal point for follow-up actions in Francophone countries.

He was Senior Health Specialist at the World Bank (AFTH2 & WBI) from 2004 to 2006 in which time he was Team leader (TL) for various health intervention, educational, management and capacity building programs mostly in Africa.

He holds a Ph.D. in health economics – University of Paris 1, Sorbonne (France); a Hospital Administration Diploma from ENSP Rennes (France); and a Diploma in Public Health from the University of Nancy (France).

David Jefferys is currently the Senior Vice President for Global Regulatory, Healthcare Policy and Corporate Affairs, Eisai Europe and Chairman of the Eisai Global Regulatory Council. He also sits as a member of the European Working Group of the UK Ministerial Industry Strategy Group and UK Innovation Board. He is Chairman of the ABPI Regulatory Affairs Group and a member of several EFPIA committees. He is also Chair of the IFPMA RSC.

Margaret Afriyie is a midwife in charge at Ahweram Community-Based Health Planning and Services (CHPS) Compound in the Ashanti Region. She is also founder of the Margaret Afriyie Mother and Child Community Initiative, a charity that seeks to educate those in the deprived areas in the importance to attend antenatal care and deliver at a health facility.

Dr. Grampp is a Director of R&D Policy at Amgen, where he leads external affairs related to biosimilars in Latin America and other regions. Prior to this role, he was Director of Regulatory Affairs, supporting regulatory agency interactions, technical strategy and submissions related to Amgen’s biosimilars development program while advocating for science-based implementation of biologics policies. Before his engagement on biosimilars, Dr. Grampp led technical teams responsible for development and quality oversight of Amgen’s biologics manufacturing processes. Dr. Grampp earned his bachelor’s degree in Chemical Engineering at the University of Wisconsin and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology. Dr. Grampp is the current Chair of IFPMA’s Biotherapeutics Group.

David King is Co-Chair of the IFPMA Ethics & Business Integrity Committee Patient Centricity Working Group. David is in the Ethics & Compliance Office at Merck Sharp & Dohme Corp. (MSD), where he provides support to MSD’s Policy, Communications, and Patient Innovation and Engagement teams. David previously worked as MSD’s global investigations and anti-corruption counsel. He joined MSD in 2011 from Arnold & Porter LLP, a multinational law firm based in Washington, D.C.

Dr Githinji Gitahi is the CEO of Amref Health Africa, the largest African-led international organization on the continent. He is also Co-Chair of the UHC2030 Steering Committee, a global World Bank and World Health Organization (WHO) initiative for Universal Health Coverage (UHC). He is also a member of the Private Sector Advisory Board of Africa CDC, the Global Health Investment Advisory Board, and of the WHO’s Community Health Worker Hub, member of the Board of Directors of The Standard Group and holds Board member positions across Amref Health Africa offices in Africa.

Soeren Mattke is not only a health policy expert but also a cardiologist. Today he is the Managing Director of RAND Health Advisory Services, the consulting practice of RAND Health. His work focuses on improving chronic illness care through redesign of delivery systems, payment reform and better products and technologies. Dr. Mattke serves as adviser to several international organizations, such as the OECD, the WHO, the European Commission and the World Economic Forum. Prior to coming to RAND, Dr. Mattke worked at the OECD in Paris on benchmarking healthcare systems in industrialized countries, in the healthcare practice of Bain & Company in Boston, at Abt Associates, a policy consulting firm in Cambridge, MA, and at Harvard University. He trained as an internist and cardiologist at the University of Munich. He lives in Boston with his wife Katharina and their three daughters and keeps his heart healthy with walking the dog, red wine and daily aspirin.

Dr. Paul Stoffels, M.D., is Chief Scientific Officer, and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. In this role, he works with R&D leaders across Johnson & Johnson to set the enterprise-wide innovation agenda and is a member of the Johnson & Johnson Executive Committee.

He began his career as a physician in Africa, focusing on HIV and tropical diseases research. Paul chairs the Johnson & Johnson R&D Management Committee and provides oversight to the Johnson & Johnson Development Corporation (JJDC) and the Johnson & Johnson innovation centers, with the goal of catalyzing innovative science and technology.

Andrea Vassalotti is the Director of Partnerships and Programmes at the World Heart Federation (WHF). The WHF is dedicated to leading the global fight against cardiovascular disease (CVD), including heart disease and stroke. With a focus on vulnerable populations, it is the only global advocacy and leadership organization bringing together the CVD community to help people lead heart-healthy lives.

In her role, Ms Vassalotti is responsible for building bridges with private industry and international organizations in order to secure funding for specific projects designed to reduce the impact of cardio-vascular diseases.

Kate Dodson is the vice president for global health at the United Nations Foundation. In this role, Kate works to ensure that the UN Foundation is delivering on its commitments to address the health-related Sustainable Development Goals and builds synergies with U.N. agencies and other key multilateral partners. Previously, Kate spent several years as the UN Foundation's director of global health and has also served as executive director of program integration, focused on cross-department and cross-issue collaboration.

Paola is the Chief Executive Officer (CEO) of Alzheimer’s Disease International. Prior to that, she was the CEO of LIFE. Her previous senior positions include Cass Business School, Tate, British Library and IIED.

She is a Non-Executive Director of the Non-Communicable Disease Alliance (NCDA) and a Trustee of The Postal Museum and Lauderdale House. Previously she was a Trustee of Shelter, the UK housing and homelessness charity and of MLA London. She holds a degree cum laude in Classics from the University of Napoli Federico II, an MA in Field and Analytical Techniques in Archaeology and an MA in Library and Information Science both from University College London.

Mrs Wendy Orchard is the Executive Director of the International Association for Suicide Prevention (IASP). She has worked in the field of suicide prevention for over 5 years coordinating the global network of suicidologists within IASP.

IASP leads the global effort in suicide prevention having developed an effective forum that is proactive in creating strong collaborative partnerships and promoting evidence-based action in order to reduce the incidence of suicide and suicidal behaviour (www.iasp.info). Established in 1960, IASP is the largest international association dedicated to suicide prevention and to the alleviation of the effects of suicide and collaborates closely with relevant international organisations

Mario is a Managing Director for the High Lantern Group, a strategic positioning firm. He advises firms, international institutions and global trade associations on their reputation and sustainability strategies, in particular in healthcare and life sciences sectors, leveraging his combined knowledge of business and the United Nations system, in particular the World Health Organization. Mario is often involved with high profile media, authoring thought pieces and has recently become a regular TV commentator. A former spokesperson and health policy and communication director of the IFPMA, Mario has promoted throughout his career pro-active and cross-sector dialogue. Mario is a Faculty Member of the World Business Angel Forum Business School where he focuses on issues related to private sector involvement in social good, sustainability, and impact investing. An Italian national, he holds a MA in Political Sciences and International Relations. Mario speaks English, French, and Italian.

Pierre Van Damme is full professor at the University of Antwerp, Faculty of Medicine and Health Sciences. He chairs the Vaccine & Infectious Disease Institute (VAXINFECTIO, University of Antwerp); VAXINFECTIO is a consortium of three research units within the university: the Laboratory of Medical Microbiology (LMM), the Laboratory of Experimental Hematology (LEH), and the Centre for the Evaluation of Vaccination (CEV). It is recognized as ‘Centre of Excellence’ of the University of Antwerp and functions as WHO Collaborating Centre for the WHO European Region for the control and prevention of infectious diseases.
The CEV was founded in 1994 by Pierre Van Damme. The centre conducts research in 5 main areas: (1) (sero-)epidemiology of infectious diseases; (2) economic evaluation of public health interventions and mathematical modelling of infectious diseases; (3) assessment of protective efficacy and effectiveness of vaccines; (4) injection and diagnostic device research; (5) kinetics of vaccine-induced antibodies, including passive transfer of maternal antibodies.

Pierre Van Damme gained his MD from the University of Antwerp in 1984. He was recruited in 1985 to work on the epidemiology and prevention of hepatitis B in institutions for the mentally retarded. He subsequently obtained post-graduate degrees in health and economics, the evaluation of human corporal damage, and a master degree in occupational health. He obtained his PhD in epidemiology and social medicine in 1994 from the University of University of Antwerp, Belgium.

Mr. Kalland is responsible for the relationship with Pharmaceutical and Healthcare Manufacturers. Development and selling of services for Manufacturers.
Responsible for two Synergy workstreams for Walgreens Boots Alliance Development GmbH (Branded Pharma & Branded non Pharma)

Andrew Jenner is an Executive Director at JS Consulting Ltd. He joined IFPMA in late 2009 as the Director responsible for Innovation, Intellectual Property (IP) & Trade. From 2013 until 2015 Andrew worked as the Executive Director of Corporate Strategy & Legal Affairs at IFPMA. Prior to joining IFPMA, he held a number of policy roles in the UK Government including the principal UN/WTO negotiator on IP, Trade & Development for the UK Intellectual Property Office. He also led the UK Government’s IP Crime Strategy which pioneered the creation of a Governmental, multi-enforcement agency & industry taskforce. Before joining Government, he worked in the automotive industry as a quality control advisor. He is a Fellow of the Chartered Institute of Management and a Member of the Institute of Engineering & Technology having a Bachelor degree in Engineering and a Master of Laws.

Dr Downham studied for a bachelor of sciences degree (with honours) in industrial biology at London South Bank Polytechnic (UK) which included a placement with Boehringer Mannheim, now Roche (Germany). He then completed a PhD in biochemical engineering (Birmingham University, UK), a post-doctoral fellowship in bio-molecular sciences (Liverpool John Moores University, UK) and a post-graduate certificate in further/higher education (Bolton Institute, UK).
He joined the biopharmaceutical industry in 1997 and has worked for Protherics (UK), Bavarian Nordic (Germany), Morphosys (Germany) and Novartis Vaccines & Diagnostics (Italy). Throughout this time Dr Downham worked on preclinical and early clinical development of vaccine, antibody or enzyme therapies for infectious, hypertension, inflammatory and oncology indications. He was a certified European Registered Toxicologist (2010-2015) and has co-authored 29 publications/abstracts and 3 international patents.
Dr Downham joined the influenza vaccine franchise of AstraZeneca/Medimmune (UK) in February 2013 as an Associate Director, Flu Manufacturing Sciences & Technology within the Biopharmaceutical Development (R&D) department.

Lembit Rägo MD, PhD was born in Tartu, Estonia, in 1955. During 1992 to 1999, he was a Professor of Clinical Pharmacology at Tartu University. He was the founder and first Director General of the Estonian Drug Regulatory Authority, State Agency of Medicines (1991-1999).

In December 1999, he joined the World Health Organization (WHO) as the Coordinator in the Quality Assurance and Safety of Medicines (QSM) team. During 2000-2001, Dr Rägo laid the foundation for the WHO Prequalification of Medicines Programme. He has also served as a Secretary of WHO’s Secretariat Committee on Research Involving Human Subjects.

Dr Rägo started working as Secretary-General of Council for International Organizations of Medical Sciences (CIOMS), located in Geneva, Switzerland from 18 April 2016. Under his leadership, CIOMS has been modernized and also runs many different technical Working Groups.

Born in London, Cary Adams has a BSc Honours degree in Economics, Computing and Statistics from the University of Bath, United Kingdom and a Masters degree (with Distinction) in Business Administration. He is a Harvard Business School Alumni having attended the School’s Executive General Management programme in 2003. In 2009, Cary made a career change, moving from the management of international businesses in the banking sector to become CEO of UICC based in Geneva.

Heidi Larson is professor of anthropology, risk, and decision science and director of the Vaccine Confidence Project in the Department of Infectious Disease Epidemiology at the London School of Hygiene and Tropical Medicine. She is also a clinical professor at the Department of Global Health at the University of Washington.

Dr. Angela Nyambura Gichaga, Chief Executive Officer, the Financing Alliance for Health (FAH) has served as a clinician, civil servant, administrator, consultant and academician. She began her career in government, serving as a frontline clinician, where she worked for the Ministry of Health of Kenya as a District Medical Officer of Health and a hospital in charge in both Meru and Garbatulla, leading ~150 multi-disciplinary team members through coordinating strategic planning, resource mobilization, service delivery, recruitment, monitoring and capacity building. She then joined the MOH HQ, where she supported health financing, co-developed national strategies and prepared reports on the country’s health achievements. Dr. Gichaga then joined McKinsey & Company’s Africa Delivery Hub (ADH), focussing on socio-economic and development issues in Africa. She now serves developing country Ministries of Health and Ministries of Finance globally, in building resilient and sustainably financed primary and community health systems as CEO of the Financing Alliance for Health. Recognition of her leadership and performance track record includes recognition as one of Fortune World’s Greatest Leaders in 2018, an Archbishop Tutu Leadership Fellowship, an Australian Leadership Award for Africa and the President Obama Mandela Washington Fellowship.

Jane M Barratt, Ph.D. is the Secretary General, International Federation on Ageing. Representing over 75 million older people through the membership of the IFA, Jane has direct responsibility for the corporation’s operational performance, quality and strategic implementation, and business development. This includes leadership at the United Nations Economic and Social Council in New York, Geneva and Vienna and the WHO. Among her many current positions Jane is a Member of Vision Academy, Director, Baycrest Health Sciences and Chair of the Education Advisory Committee, Associate Scientist, Sinai Health System, Member, Global Committee for the DR Barometer Program, and Member of the International Council for Adult Immunisation. She is a former member of the World Economic Forum’s Global Agenda Council on Ageing and until recently Chair, Standing Selection Committee for the Networks of Centres of Excellence of Canada and a former member of the Global Agenda Council on Ageing for the World Economic Forum.

In her role, Nanette oversees an international business and is responsible for the development and delivery of innovative vaccines that address serious and life-threatening conditions, helping to protect communities around the world. She is also the Chair of the International Federation of Pharmaceuticals and Manufacturers Association (IFPMA) Vaccine CEO Steering Committee, advocating for policies and practices that will enable greater access and affordability to vaccines in low and middle-income countries.

Nanette leads a global team of 1,500 colleagues and manages a diverse vaccines portfolio aimed at protecting lives at all stages, from infants to older adults. She and her team also partner with governments, civic organizations, and others in the biopharmaceutical industry to accelerate global public health progress.

Prior to her current position, Nanette was Regional President, Emerging Markets, for Pfizer’s Innovative Health business. In this role, she led business operations in over 100 countries across Latin America, Africa, the Middle East, and Asia, spanning Pfizer’s core therapeutic areas including vaccines, oncology, inflammation and immunology, internal medicine and rare disease. During her 15+ year tenure at Pfizer, Nanette has held numerous leadership positions in both developed and emerging markets, driving continuous growth for the businesses she managed and bringing novel medicines and access solutions to patients.

Emilio A. Emini, Ph.D., is Senior Vice President of Vaccine Research and Development at Pfizer Inc., a position into which he transitioned subsequent to Pfizer’s acquisition of Wyeth Pharmaceuticals in late 2009. Dr. Emini joined Wyeth as Executive Vice President of Vaccine Research and Development in November 2005. At Wyeth, he led the R&D efforts that resulted in licensure of Prevnar 13, Pfizer’s vaccine for the prevention of pneumococcal disease. Currently, Dr. Emini leads Pfizer’s worldwide vaccine research and development programs.

Ruth March, VP and Head of Personalised Healthcare and Biomarkers, leads AstraZeneca’s function of world class diagnostic and biomarker science experts, delivering companion diagnostic tests to target AZ drugs to the right patients across each therapy area and all phases of development. She has driven adoption of Personalised Healthcare approaches by 70% of AstraZeneca’s pipeline, partnering with a strategic network of diagnostic companies to ensure delivery to global clinical trials and marketed products.

Dr. James Headen Pfitzer was appointed Director of Access Accelerated in September 2017. Previously, James spent 10 years at the World Health Organization (WHO) Headquarters in Geneva, Switzerland, where he handled strategy, engagement and policy for the Assistant Director Generals of Health Systems and Innovation and Global Health Security. Prior to joining WHO, James was Associate Legal Officer at the World Trade Organization in Geneva. James is an American trained lawyer with an LLM in trade and development and holds a PhD in international law with a focus on due process protections in dispute settlement from the University of Bern, Switzerland.

Dr. Anke Post is a medical fellow in neuroscience discovery and clinical investigation at Eli Lilly and Company’s Erl Wood research facility in the UK. The majority of her 20 years of professional activity has been dedicated to preclinical research, to medical duties and to clinical (pharmaceutical) development. Dr. Post completed post-graduate studies in basic and clinical neuroscience research at the Humboldt University of Berlin and at the Max-Planck Institute of Psychiatry (MPI) in Munich, Germany. She joined Lilly in 2011 after several years leading clinical trials for neuroscience development programs as well as in business development activities. At Lilly she works as clinical lead for several important neuroscience projects, is a member of the drug discovery leadership team, is the lead physician for the early clinical portfolio.

Lois Privor-Dumm is the Director of Policy, Advocacy and Communications at the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health. Her team focuses on the translation of evidence to policy to facilitate vaccine decision making and support advocacy in low- and middle-income countries, including India, Nigeria, and Pakistan. For nearly ten years, she has worked with stakeholders in India to synthesize and communicate evidence to build public and political support, as well as expert capacity for new vaccine advocacy and policy making. She has trained hundreds of pediatricians and public health professionals in multiple countries to build their skills in advocating for pneumonia and diarrhea prevention.

Previously, Lois was the Director of Access and Implementation for Gavi’s PneumoADIP and Director of Communications and Strategy for the Hib Initiative, both based at Johns Hopkins and with the mission of accelerating vaccine introduction to reduce serious childhood diseases. She joined Johns Hopkins in 2005, after spending eighteen years working in various industry positions. She led a team that introduced Wyeth’s (now Pfizer) Prevnar® pneumococcal conjugate vaccine in the U.S. and in other countries. Lois’s experience spans many regions around the world, including the U.S., Latin America, Europe, the Middle East, and Africa.

Lois holds a Master’s degree in International Business Studies (now IMBA) from the University of South Carolina, studied European politics and French in Louvain-la-Neuve and completed her internship at Merck Sharp & Dohme in Brussels, Belgium.

Jean-Christophe Tellier Jean-Christophe Tellier joined UCB in 2011. He became UCB’s Chief Executive Officer on January 1, 2015 after having successfully led UCB’s BioBrands and Solutions division as Executive Vice President. He is a member of the Board of Directors of UCB.
Jean-Christophe Tellier is an experienced global leader. He was trained as a Medical Doctor and specialized in rheumatology. He has built a distinguished 30+ year career in the biopharmaceutical industry, taking on different global leadership responsibilities in different parts of the world. His patient-centric approach, his passion for science, combined with his strategic and operational skills, have allowed him to significantly contribute to UCB’s success in recent years. Jean-Christophe has led the integration of UCB’s sustainability approach into the company’s strategy. He has also been instrumental in humanizing UCB’s approach towards patients, developing the company’s Patient Value Strategy. For Jean-Christophe “engaging the patient in our vision is the best way for our company to be successful in the long term. Having a holistic view of a patient, of his/her life in his/her environment is essential to ensure effective treatment”. Jean-Christophe also believes that “all healthcare players - physicians, payors, carers, industry and academia - should cooperate even more effectively and become stronger partners sharing a same goal: improving patient care”.
Key positions Prior to UCB, Jean-Christophe held the following positions: 2009 Ipsen: President and General Manager of Ipsen’s North American operations 2008 Macrogenics: Maryland-based public biotechnology company Executive Vice President and Chief Commercial Officer 1989 – 2008 Novartis: CEO of Novartis Pharma France CEO of Novartis Pharma Belgium.
Jean-Christophe is currently IFPMA President and Chair of the IFPMA CEO Steering Committee, Member of the Board of the European Federation of Pharmaceutical Associations (EFPIA) and Vice-Chair

Ronald T. Piervincenzi, Ph.D., is the Chief Executive Officer of the United States Pharmacopeial Convention (USP). For 12 years Dr. Piervincenzi was a partner and leader in McKinsey & Company's Global Pharmaceutical and Medical Products Practice where, among other responsibilities, he launched McKinsey's global drug safety, medical and regulatory service line. Most recently, as a VP in Development Sciences with Biogen Idec, he launched a new group (Value-Based Medicine) focused on applying tools and technologies of personalized medicine to the multiple sclerosis disease area. Dr. Piervincenzi earned his M.S. and Ph.D. from Duke University in Biomedical Engineering, with research focused on protein engineering. He is the founder of multiple non-profits in the community service and scientific spaces including serving currently as Board Chair for the Newark Mentoring Movement and the NextStep Translational Research Foundation.

Adebayo Alonge, pharmacist and entrepreneur, talks to IFPMA about why it is important to bring universal health coverage (UHC) to his native Africa, especially rural areas, how to build up local healthcare systems, foster home-grown hi-tech pharma – and fight quack medicines.
Adebayo has more than eight years’ experience in market development and strategy consulting across Africa, working with BCG, BASF, Roche and Sanofi. In late 2017 he co-founded the start-up RxAll – developing a handheld nano-scanner based on AI technology which enables users to verify the authenticity of medicines and help stop the scourge of fake drugs. So far, RxAll has deployed around 70 devices to the food and drug administration agencies of five African countries as well as 200 pharmacies across Nigeria and Kenya. The company's goal is to provide every pharmacy with such a device across Africa.

James joined the IFPMA as Executive Director of Global Health in January 2021, where he is responsible for leading the delivery of IFPMA’s relevant policy and advocacy work. In his previous role as Head of Corporate Government Affairs at GSK, James led engagement with the UK Government spanning GSK’s pharmaceuticals, vaccines, and consumer businesses. James was a member of the UK Government’s Life Science Strategy Board and Vice-Chair of Business at OECD’s Healthcare Committee. James also led GSK’s strategy and advocacy on Antimicrobial Resistance (AMR). He advised on AMR policy development at the WHO, UN, EU Commission, the O’Neill Review and National Governments. He was Chair of the Industry AMR Committee, in the Founding team of the AMR Action Fund and led the development of the Davos Declaration and 2016 UNGA Industry AMR Roadmap.

James joined the IFPMA as Executive Director of Global Health in January 2021, where he is responsible for leading the delivery of IFPMA’s relevant policy and advocacy work. In his previous role as Head of Corporate Government Affairs at GSK, James led engagement with the UK Government spanning GSK’s pharmaceuticals, vaccines, and consumer businesses. James was a member of the UK Government’s Life Science Strategy Board and Vice-Chair of Business at OECD’s Healthcare Committee. James also led GSK’s strategy and advocacy on Antimicrobial Resistance (AMR). He advised on AMR policy development at the WHO, UN, EU Commission, the O’Neill Review and National Governments. He was Chair of the Industry AMR Committee, in the Founding team of the AMR Action Fund and led the development of the Davos Declaration and 2016 UNGA Industry AMR Roadmap.

Guilherme Cintra joined IFPMA in March 2005 and leads IFPMA’s advocacy with the WTO and the WIPO and runs the IFPMA Socio-Economic Research Network, which conducts international research and analytical work on different subjects relating to intellectual property, pharmaceutical innovation, and access to medicines. Guilherme studied economic history and social sciences in Geneva and Belo Horizonte. In his free time, he enjoys rock climbing and snowboarding. There are rumors he makes good capirinhas.

Komal is an experienced corporate attorney and a trusted government advisor. Komal’s expertise allows her to work across multiple sectors to resolve complex domestic and international policy and business challenges. Her thorough understanding of the law as well as a strong grasp of the trade and economic implications, has allowed her to better understand the practical challenges raised by both industry and governments, as new policies are considered. This skill set enables her to provide a policy solution for developed and emerging markets from a business and legal perspective. She has counseled the healthcare and lifesciences, technology, media and entertainment and other innovative industries. Currently, she is the Associate Director for Intellectual Property (IP) and Trade Policy, at the International Federation of Pharmaceutical Manufactures and Associations (IFPMA), which represents leading research-based biopharmaceutical companies as well as national and regional industry associations. She heads the work with UN Members States, Multi-Lateral Organisations and Regional Associations to promote global health solutions by advocating international best practices for intellectual property protection, removal of market access barriers and the need to create a sustainable ecosystem necessary to incentivise biomedical innovation. Prior to joining IFPMA, Komal led the United States Patent & Trademark Office’s (USPTO) attaché program in South Asia. She was the principal strategic advisor to the United States Government (USG) on all aspects of Intellectual Property for India, Pakistan, Sri Lanka, Nepal, Bangladesh, Bhutan, Afghanistan and the Maldives (collectively South Asia) and was responsible for promoting the development and improvement of IP systems in these countries. She led negotiations with South Asian Governments relating to IP policies initiatives of the USG. Several capacity building programs aimed at creating a sustainable innovation ecosystem one that prom